Here is my brief for why I bought the following growth counters of my portfolio. Click here to read why I buy my income counters.
| Counter | Position | Reason for buying | First bought | Avg. Price* |
| Raffles Medical Group | 3.5% | Expansion of Raffles Hospital locally and China. Cash generating despite expansion. | May 2016 | $1.15 |
| iFAST | 3.3% | An all-in-one financial services. Increasing recurring revenue. Good track record of executing its plan. Big potential China market. | Sep 2017 | $0.93 |
| Food Empire | 2.5% | Established leader for instant coffee in Russia/Ukraine. Successful diversification to Vietnam and potential growth for ingredient segment. | Mar 2018 | $0.64 |
| SaaS | 4.9% | A mini-fund of SaaS companies that have good growth potential in the coming decade. | Feb 2020 | – |
| MFRS2020 | 4.0% | Micro-cap recommendations from Motley Fool. Most companies have market cap of less than US$5 bil. The service aims to double the portfolio in 5 years. | Dec 2019 | – |
| Arista Networks | 4.0% | Disruptor to CISCO and gaining market shares for network. Strong management team and will benefit from increasing usage of cloud services | May 2018 | $240.36 |
| Intuitive Surgical | 3.5% | Leader in robotic surgery and should be able to continue to grow with huge market. | Nov 2019 | $536.63 |
| Ulta Beauty | 3.4% | Reacted to disruption and developed omni-channel to grow its business. Strong CEO who should be able to continue to grow the company. | Mar 2018 | $247.18 |
| Apple | 2.9% | Huge customer base for expansion of its services and wearable market, resulting in more recurring revenue. | Dec 2018 | $168.55 |
| Starbucks | 2.9% | Global brand and fast expansion in China market. Collaboration with Nestle provides another source of revenue. | Mar 2018 | $66.71 |
| VISA | 2.5% | Top payment services that have benefitted with the increasing cashless payment. | Sep 2018 | $157.38 |
| The Walt Disney Company | 2.3% | Strong content creator that allows it to monetise in various ways. Disney+ should benefit it in the long term. | Mar 2018 | $117.98 |
| Illumina | 1.9% | Leader in genetic sequencing and should continue to benefit from the increase in use of genetics in healthcare. | Oct 2019 | $309.33 |
| Adobe | 1.8% | Transformation into subscription services of its popular software has increased its recurring revenue. Reaches out to a larger market with a lower pricing. | Nov 2019 | $324.04 |
*This differs from my new portfolio’s price which is based on 31 Dec 2019 closing.
Discover more from The Fat Investor
Subscribe to get the latest posts sent to your email.
The Fat Investor 